JP2017531013A5 - - Google Patents

Download PDF

Info

Publication number
JP2017531013A5
JP2017531013A5 JP2017520388A JP2017520388A JP2017531013A5 JP 2017531013 A5 JP2017531013 A5 JP 2017531013A5 JP 2017520388 A JP2017520388 A JP 2017520388A JP 2017520388 A JP2017520388 A JP 2017520388A JP 2017531013 A5 JP2017531013 A5 JP 2017531013A5
Authority
JP
Japan
Prior art keywords
liver disease
composition
item
fatty liver
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017520388A
Other languages
English (en)
Japanese (ja)
Other versions
JP6761410B2 (ja
JP2017531013A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/055487 external-priority patent/WO2016061195A1/en
Publication of JP2017531013A publication Critical patent/JP2017531013A/ja
Publication of JP2017531013A5 publication Critical patent/JP2017531013A5/ja
Application granted granted Critical
Publication of JP6761410B2 publication Critical patent/JP6761410B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017520388A 2014-10-15 2015-10-14 グルココルチコイドおよびミネラル・コルチコイドレセプターアンタゴニストを使用する脂肪肝疾患の処置 Active JP6761410B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462064358P 2014-10-15 2014-10-15
US62/064,358 2014-10-15
US201462092041P 2014-12-15 2014-12-15
US62/092,041 2014-12-15
PCT/US2015/055487 WO2016061195A1 (en) 2014-10-15 2015-10-14 Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

Publications (3)

Publication Number Publication Date
JP2017531013A JP2017531013A (ja) 2017-10-19
JP2017531013A5 true JP2017531013A5 (https=) 2018-11-22
JP6761410B2 JP6761410B2 (ja) 2020-09-23

Family

ID=55747256

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017520388A Active JP6761410B2 (ja) 2014-10-15 2015-10-14 グルココルチコイドおよびミネラル・コルチコイドレセプターアンタゴニストを使用する脂肪肝疾患の処置

Country Status (22)

Country Link
US (5) US10238659B2 (https=)
EP (2) EP3206692B1 (https=)
JP (1) JP6761410B2 (https=)
KR (1) KR102435956B1 (https=)
CN (2) CN111557942B (https=)
AU (1) AU2015333645B2 (https=)
BR (1) BR112017007860B1 (https=)
CA (1) CA2964625C (https=)
DK (1) DK3206692T3 (https=)
ES (1) ES2978871T3 (https=)
FI (1) FI3206692T3 (https=)
IL (1) IL251729B (https=)
MX (1) MX2017004943A (https=)
NZ (1) NZ731060A (https=)
PH (1) PH12017500710B1 (https=)
PL (1) PL3206692T3 (https=)
PT (1) PT3206692T (https=)
RU (1) RU2718921C2 (https=)
SG (1) SG11201703024VA (https=)
UA (1) UA123537C2 (https=)
WO (1) WO2016061195A1 (https=)
ZA (1) ZA201702813B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111557942B (zh) 2014-10-15 2023-10-03 科赛普特治疗学股份有限公司 使用糖皮质激素和盐皮质激素受体拮抗剂的脂肪肝疾病治疗
JP7196201B2 (ja) 2018-06-04 2022-12-26 コーセプト セラピューティクス, インコーポレイテッド ピリミジンシクロヘキセニル糖質コルチコイドレセプター調節因子
EP4653047A3 (en) 2019-03-18 2026-02-18 Nieman, Lynnette K. Mifepristone for use in improving insulin sensitivity
KR102911885B1 (ko) * 2020-05-06 2026-01-12 코어셉트 쎄라퓨틱스 인코포레이티드 피리미딘 사이클로헥실 글루코코르티코이드 수용체 조절제의 다형체
JP7474869B2 (ja) * 2020-05-06 2024-04-25 コーセプト セラピューティクス, インコーポレイテッド ピリミジンシクロヘキシルグルココルチコイド受容体モジュレーターの製剤
KR102481705B1 (ko) * 2020-08-04 2022-12-27 연세대학교 산학협력단 트리아졸 유도체를 유효성분으로 포함하는 간 섬유증의 예방 또는 치료용 조성물
AU2021409656B2 (en) * 2020-12-21 2025-04-10 Corcept Therapeutics Incorporated Method of preparing pyrimidine cyclohexyl glucocorticoid receptor modulators
CA3217413A1 (en) * 2021-05-05 2022-11-10 Ada Lee Methods for reducing liver fat and for treating fatty liver disorders
WO2025174745A1 (en) * 2024-02-12 2025-08-21 Corcept Therapeutics Incorporated MIRICORILANT TREATMENT FOR FATTY LIVER DISEASES and its EFFECTS on LIVER FAT CONTENT, FATTY ACIDS, ACYLGLYCEROLS, and SECONDARY BILE ACIDS
WO2025255357A1 (en) * 2024-06-06 2025-12-11 Corcept Therapeutics Incorporated Methods for preparing and maintaining livers and portions thereof for liver transplantation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2153546A (en) 1936-07-29 1939-04-11 Universal Draft Gear Attachmen Hand brake actuating mechanism
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
GB0213745D0 (en) * 2002-06-14 2002-07-24 Univ Edinburgh Enzyme
WO2004009017A2 (en) 2002-07-18 2004-01-29 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
ATE463479T1 (de) 2005-05-18 2010-04-15 Merck Sharp & Dohme D-homoandrosta-17-yl-carbamat-derivate als selektive glucocorticoid-rezeptor-liganden
WO2007022518A2 (en) * 2005-08-19 2007-02-22 Amylin Pharmaceuticals, Inc. New uses of glucoregulatory proteins
BRPI0616370A2 (pt) * 2005-09-19 2011-06-14 Johnson & Johnson Pharmaceutical Res & Dev L L C modulaÇço da expressço de receptor de glucocorticàide
GB0601092D0 (en) * 2006-01-19 2006-03-01 Daniolabs Ltd The Prevention Of Systemic Side-Effects Of Glucocorticoids
PL2032134T3 (pl) 2006-05-09 2015-11-30 Genzyme Corp Sposoby leczenia stłuszczeniowej choroby wątroby obejmujące hamowanie syntezy glikosfingolipidów
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
CN101679445A (zh) 2007-04-13 2010-03-24 先灵公司 嘧啶二酮衍生物及其应用
US8003689B2 (en) 2008-06-20 2011-08-23 Gtx, Inc. Metabolites of selective androgen receptor modulators and methods of use thereof
KR101739994B1 (ko) 2009-04-03 2017-05-25 에프. 호프만-라 로슈 아게 프로판-1-술폰산 {3-[5-(4-클로로-페닐)-1H-피롤로[2,3-b]피리딘-3-카르보닐]-2,4-디플루오로-페닐}-아미드 조성물 및 그의 용도
MY161170A (en) * 2011-03-18 2017-04-14 Corcept Therapeutics Inc Pyrimidine cyclohexyl glucocorticoid receptor modulators
CN111557942B (zh) 2014-10-15 2023-10-03 科赛普特治疗学股份有限公司 使用糖皮质激素和盐皮质激素受体拮抗剂的脂肪肝疾病治疗

Similar Documents

Publication Publication Date Title
JP2017531013A5 (https=)
RU2017114596A (ru) Лечение жировой болезни печени с применением антагонистов глюкокортикоидных и минералокортикоидных рецепторов
JP2014015465A5 (https=)
JP2018510139A5 (https=)
JP2016505614A5 (https=)
JP2021513534A5 (https=)
JP2011137045A5 (https=)
AR077516A1 (es) Composiciones farmaceuticas de uso oftalmico de antagonistas del receptor dp2. uso. compuesto.
JP2020521766A5 (https=)
AR072241A1 (es) Antagonistas de aminoalquilbifenilo n,n-disustituidos de receptores de prostaglandina d2 y composiciones farmaceuticas que los comprenden
JP2016516043A5 (https=)
EA201400234A1 (ru) Фунгицидные замещенные 1-{2-[2-галоген-4(4-галогенфенокси)фенил]-2-алкинилоксиэтил}-1н-[1,2,4]триазолные соединения
JP2016537478A5 (https=)
JP2016515096A5 (https=)
JP2016503052A5 (https=)
JP2016503797A5 (https=)
EA201400232A1 (ru) Фунгицидные замещенные 1-{2-[2-галоген-4-(4-галогенфенокси)фенил]-2-алкокси-2-циклилэтил}-1н-[1,2,4]триазольные соединения
JP2015512946A5 (https=)
JP2006524660A5 (https=)
EA201592020A1 (ru) Новая композиция для неалкогольной жировой болезни печени (нажбп)
JP2014511891A5 (https=)
JP2018135343A5 (https=)
RU2016133471A (ru) Композиции и способы для лечения диабета и заболеваний печени
JP2017533263A5 (https=)
EA201600241A1 (ru) Замещенные (2r,3r,5r)-3-гидрокси-(5-пиримидин-1-ил)тетрагидрофуран-2-илметил арил фосфорамидаты